Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.

O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators.

Am Heart J. 2010 May;159(5):841-849.e1. doi: 10.1016/j.ahj.2010.02.023. Erratum in: Am Heart J. 2012 May;163(5):900.

PMID:
20435194
2.

Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).

Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA.

Am J Cardiol. 2012 Dec 15;110(12):1803-8. doi: 10.1016/j.amjcard.2012.08.016. Epub 2012 Sep 19.

PMID:
22999071
3.

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.

Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M; EVEREST Investigators.

J Am Coll Cardiol. 2008 Nov 11;52(20):1640-8. doi: 10.1016/j.jacc.2008.07.056.

4.

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA.

J Card Fail. 2005 May;11(4):260-9.

PMID:
15880334
5.

Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.

Payvar S, Spertus JA, Miller AB, Casscells SW, Pang PS, Zannad F, Swedberg K, Maggioni AP, Reid KJ, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators.

Eur J Heart Fail. 2013 Dec;15(12):1382-9. doi: 10.1093/eurjhf/hft113. Epub 2013 Jul 15.

6.

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.

Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA.

J Am Coll Cardiol. 2007 Jun 5;49(22):2151-9. Epub 2007 May 18.

7.

A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.

Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F.

Heart Fail Rev. 2012 May;17(3):485-509. doi: 10.1007/s10741-011-9280-0.

PMID:
21932146
8.

EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.

Cavalcante JL, Khan S, Gheorghiade M.

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1331-8. doi: 10.1586/14779072.6.10.1331.

PMID:
19018685
9.

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.

Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M; EVEREST Investigators.

Eur Heart J. 2011 Oct;32(20):2563-72. doi: 10.1093/eurheartj/ehr238. Epub 2011 Jul 23.

PMID:
21785107
10.

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators.

JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum in: JAMA. 2013 Apr 10;309(14):1461.

PMID:
23478743
11.

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.

Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC Jr, Grinfeld L, Maggioni AP, Udelson JE, Zimmer CA, Ouyang J, Chen CF, Gheorghiade M; EVEREST Investigators.

Eur Heart J. 2009 Jul;30(13):1666-73. doi: 10.1093/eurheartj/ehp144. Epub 2009 May 2.

PMID:
19411662
12.

Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).

Greene SJ, Harinstein ME, Vaduganathan M, Subačius H, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Butler J, Gheorghiade M; EVEREST Trial Investigators.

Am J Cardiol. 2012 Dec 1;110(11):1657-62. doi: 10.1016/j.amjcard.2012.07.035. Epub 2012 Aug 21.

PMID:
22917555
13.

Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.

Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subačius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M.

Am Heart J. 2013 Feb;165(2):216-25. doi: 10.1016/j.ahj.2012.11.004. Epub 2012 Dec 29.

PMID:
23351825
14.

Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.

Pang PS, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni AP, Grinfeld L, Zannad F, Burnett JC Jr, Ouyang J, Udelson JE, Konstam MA.

Am Heart J. 2011 Jun;161(6):1067-72. doi: 10.1016/j.ahj.2011.02.027.

PMID:
21641352
15.

Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, Butler J, Gheorghiade M; EVEREST trial investigators.

Circ Heart Fail. 2012 Nov;5(6):750-8. doi: 10.1161/CIRCHEARTFAILURE.112.970525. Epub 2012 Oct 9.

16.

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1319-31. Epub 2007 Mar 25.

PMID:
17384437
17.

Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).

Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M; EVEREST Trial Investigators.

Am J Cardiol. 2013 Feb 15;111(4):574-81. doi: 10.1016/j.amjcard.2012.10.042. Epub 2012 Dec 1.

PMID:
23206923
18.

Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial.

Mentz RJ, Chung MJ, Gheorghiade M, Pang PS, Kwasny MJ, Ambrosy AP, Vaduganathan M, O'Connor CM, Swedberg K, Zannad F, Konstam MA, Maggioni AP.

Am Heart J. 2012 Dec;164(6):884-92.e2. doi: 10.1016/j.ahj.2012.09.011. Epub 2012 Oct 29.

PMID:
23194489
19.

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.

Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators.

J Cardiovasc Med (Hagerstown). 2012 Jul;13(7):415-22. doi: 10.2459/JCM.0b013e328355a740.

PMID:
22673023
20.

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.

JAMA. 2004 Apr 28;291(16):1963-71.

PMID:
15113814

Supplemental Content

Support Center